Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4149 USD | +2.95% | -2.12% | -5.68% |
May. 16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
Apr. 29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.68% | 21.11M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.52% | 21.6B | |
-12.38% | 22.31B | |
-6.64% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed